Evidence map›Paper›PMID 42179969›Full record

ArticleMolecular therapy. Oncology2026

Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.

Rachael Mooney, Gary Ngai, Gurmeet Kaur, Elaine Y Kang, Jacqueline Lara, Eslam E Abd El-Fattah, Patricia Huang, Linda Flores, Marisa McDonald, Min Talley and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rachael MooneyDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.
Gary NgaiDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.
Gurmeet KaurDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.
Elaine Y KangDepartment of Immuno-Oncology, City of Hope Beckman Research Institute, Duarte, CA, USA.
Jacqueline LaraDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.
Eslam E Abd El-FattahDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.
Patricia HuangCenter for Biomedicine and Genetics GMP Manufacturing Facility, City of Hope, Duarte, CA, USA.
Linda FloresDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.
Marisa McDonaldDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.
Min TalleyDepartment of Biostatistics and Mathematical Oncology, City of Hope Beckman Research Institute, Duarte, CA, USA.
Mohamed HammadDepartment of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, 11100 Euclid Avenue, Lakeside, Cleveland, OH 44106, USA.
Michael LaidlawDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.
Ashley AlamilloCalidi Biotherapeutics, San Diego, CA, USA.
Duong Hoang NguyenCalidi Biotherapeutics, San Diego, CA, USA.
Maciej S LesniakDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
David T CurielDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Marcin KortylewskiDepartment of Immuno-Oncology, City of Hope Beckman Research Institute, Duarte, CA, USA.
Antonio F SantidrianCalidi Biotherapeutics, San Diego, CA, USA.
Thanh DellingerDivision of Gynecologic Oncology, Department of Surgery, City of Hope Beckman Research Institute, Duarte, CA, USA.
Karen S AboodyDepartment of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OVCA) is an aggressive and often recurrent malignancy with limited long-term responses to standard chemotherapy. To address the urgent need for novel, targeted therapies, we evaluated the efficacy of a tumor-tropic neural stem cell (NSC) platform delivering a conditionally replicative adenovirus (CRAd), NSC.CRAd-S-pk7, in preclinical models of advanced OVCA. A single intraperitoneal dose of NSC.CRAd-S-pk7 delivering 3 × 10

Indexed as

adenoviral vectorcell-based deliverydose regimenimmune activationintraperitoneal metastasesintraperitoneal therapyneural stem cellsoncolytic adenovirusovarian cancerviro-immunotherapy

Identifiers

PMID42179969
PMCPMC13196415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.